KYLYS AESTHETICS SA secures CHF 1 Million
Share this article
The Geneva-based startup and FONGIT alumni develops next-generation hyaluronic acid-based medical devices.
KYLYS AESTHETICS SA, a Swiss biotech clinical stage company pioneering high-performance regenerative aesthetic solutions, proudly announces the successful closing of a CHF 1 million fundraising round by existing and new investors. This capital injection will allow the company to advance the development and clinical validation of its Class III medical device based on patented hyaluronic acid technology. K
YLYS AESTHETICS’ flagship product is an innovative injectable solution designed for aesthetic application. Leveraging a unique technology developed in collaboration with the University of Geneva, the company aims to provide safer, longer-lasting, and more natural outcomes in soft tissue regeneration and rejuvenation. This financing round represents a strong vote of confidence in the company’s vision, technology, and management team. The funds will support ongoing clinical work, regulatory submissions, the development of new products and preparation for market entry.
The company extends its heartfelt gratitude to its partners who contributed to this fundraising round, including The Berlin Angel Fund, Angels from Business Angel Club Berlin-Bradenburg, FONGIT, and its private and strategic investors. It also acknowledges the invaluable support of Swiss programs and institutions such as Innosuisse, Venturelab, Swissnex, Office de Promotion des Industries et des Technologies (OPI), University of Geneva, University of Bern, the Swiss Institute for Translational and Entrepreneurial Medicine (sitem-insel) and Genolier Innovation Hub.
➡️ Source: KYLYS AESTHETICS SA | 📸 ©KYLYS AESTHETICS SA. L to R: Bryan Porcello (2), Dr. Alexandre Porcello (3), Prof. Oliver Jordan (4).